Prelude TherapeuticsPRLD
NASDAQPharmaceuticals
No cached AI snapshot yet for PRLD.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
79 employees63.00M shares outstandinglisted 2020-09-25
Next earnings ~May 5, 2026
About Prelude Therapeutics
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
Latest News
Showing market-wide stock news
Five Reasons Treasury Bond Yields Will Plummet In The Next Year
Fed: A rate increase backed by hawkish dots and rhetoric would support short-term yields
Euro zone yields linger at multi-year peaks as traders brace for Fed rate decision
US Dollar: Warsh guidance keeps Greenback supported – ING
United States Dollar Index (DXY) eases from two-week top, holds above 99.50 ahead of Fed
Equities: Consumer sectors under pressure from energy shock – Danske Bank
Related Stocksin Pharmaceuticals
Ready to see the live AI view on PRLD?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing PRLD side-by-side with live signals.